Braidwell LP is a Stamford, Connecticut-based investment firm focused on life sciences and healthcare, investing across public equities, private markets, and structured capital. Founded in 2021 by Alex Karnal and Brian Kreiter, the firm launched with approximately $3.5 billion and operates a flagship hedge fund, a credit platform, and an early-stage incubator (Braidwell Labs).
67% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $143.0M (across 11 rounds with reported amounts).
Portfolio
12
Fund Size
$3.5B
Top Stage
Series C
Last 12 Mo
0
Team
Alex Karnal
Chief Investment Officer, Partner, Co-Founder
Brian Kreiter
Chief Executive Officer, Partner, Co-Founder
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Surrozen | Series D | $175M | Mar 2025 |
| PPerceive Pharma | Series A | $15M | Feb 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
| EElektrofi | Series C | $112.3M | Oct 2024 |
 Bicara Therapeutics | Series C | $165M | Dec 2023 |
| BBicara | Series C | $165M | Dec 2023 |
 Caris Life Sciences | Unknown | — | Jan 2023 |
 Jade Biosciences | Unknown | $95M | — |
 Oruka Therapeutics | Growth | $275M | — |
| PPerceive Biotherapeutics | Series B | $78M | — |
Top Co-Investors
Deep Track Capital5 shared
Catalio Capital Management4 shared
Logos Capital3 shared
Samsara BioCapital3 shared
RA Capital Management3 shared
RTW Investments, LP3 shared
Fairmount Funds Management3 shared
Deerfield3 shared
BVF Partners L.P.2 shared
SR One2 shared
General Catalyst2 shared
Marshall Wace2 shared
Eli Lilly and Company2 shared
Blackstone Inc.2 shared
Commodore Capital2 shared
Frazier Life Sciences2 shared
Perceptive Advisors2 shared
RD Fund2 shared
Access Biotechnology2 shared
Last updated: 8 September 2026